Skip to main content
. Author manuscript; available in PMC: 2015 Nov 16.
Published in final edited form as: Pediatr Blood Cancer. 2012 Dec 31;60(7):1108–1112. doi: 10.1002/pbc.24457

TABLE I.

Characteristics of Patients Enrolled on Two Prospective Phase II Clinical Trials for Children With Desmoid Tumor

COG ARST0321 POG 9650
Years of accrual 2004–2009 1997–2001
Period of accrual 63 months 35 months
Eligible subjects 59 27
Age at Dx [median (range)] 13 years (<1–18 years) 10 years (<1–18 years)
Males/females 30/29 20/7
Newly diagnosed 22 (37%) 11 (41%)
Recurrent disease 37 (63%) 16 (59%)
Prior chemotherapy 15/37 (41%) NA
Prior radiation therapy 6/37 (16%) NA
Multifocal disease 13/55 (24%); 4 Unk NA
FHx of FAP 10/50 (20%); 9 Unk NA

COG, Children’s Oncology Group; POG, Pediatric Oncology Group; FAP, familial adenomatous polyposis; Dx, diagnosis; NA, not available; Unk, unknown.